Our data suggest the TGF-β/ATF3/lnc-SCARNA10 axis contributes to liver fibrosis by activating HSCs, which broaden the regulatory network of ATF3 and deepen our understanding on the molecular mechanism of liver fibrosis, providing that the modulation of ATF3 in activated HSCs may represent a novel therapeutic approach against liver fibrosis. The gene discussed is TGFB1; the disease is Hepatic fibrosis.